Heron Says ZYNRELEF Commercially Available In U.S As Extended-release Local Anesthetic

(RTTNews) - Heron Therapeutics Inc. (HRTX) said that ZYNRELEF is now commercially available at all national wholesalers and the largest specialty distributors in the United States, as the first and only extended-release dual-acting local anesthetic.

ZYNRELEF is local anesthetic for postoperative pain designated by the the U.S. Food and Drug Administration to be extended-release for up to 72 hours after surgery, which may help patients and healthcare providers reduce overreliance on opioids but also mitigate exposure to their unwanted side effects and the potential for long-term safety risks like opioid misuse, abuse, or addiction, the company said in a statement.

ZYNRELEF was approved by the FDA on May 12 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.